AGM Presentation
Filed with ASX · · 18 pages · English
Summary by 6ix AI
Recce Pharmaceuticals Ltd. has released a presentation for its Annual General Meeting, detailing its corporate goals and clinical trial progress. The presentation outlines the company's development of a new class of synthetic anti-infectives and highlights its ongoing clinical trials and partnerships. It also discusses the company's capital structure and market opportunities in the global diabetic foot infection and sepsis markets. The document emphasizes the importance of regulatory approvals and collaborations to expand Recce's presence in the USA and Southeast Asia.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/agm-presentation-66
Recce Pharmaceuticals Ltd. on 6ix
In the deck
Story so far
Earlier from Recce Pharmaceuticals
- Phase II ABSSSI Clinical Trial Advances to Final Stages
- Efficacy Data & Approval to Continue Ph II ABSSSI Trial
- Ph II ABSSSI Trial Recruitment and Dosing Passes Halfway
- Notice of Special General Meeting/Proxy Form
- Recce Pharmaceuticals Announces Successful Completion of Share Purchase Plan
Later from Recce Pharmaceuticals
- Ethics Approval for Registrational Ph3 R327G Clinical Trial
- AUD $6.75m R&D Rebate Approved
- Australia Patent Granted for RECCE Anti-Infectives
- Regulatory Approval for Registrational Phase 3 R327G Trial
- Patient Dosing Complete in Phase II ABSSSI Trial of R327G
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals